pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vtama
drug
save

tapinarof

Marketedupdated 3mo ago
by Dermavant Sciences Inc
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying tapinarof

  • phase3A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitisactive not recruitingn=187
  • phase3Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)enrolling by invitationn=40
  • phase1A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.completedn=575
  • phase3Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjectsactive not recruitingn=58
  • phase1Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancernot yet recruitingn=30
  • phase2Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratodermarecruitingn=6
  • phase3Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasiscompletedn=560
  • phase2Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitiscompletedn=36
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
May 23, 2027
277 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

  • Dec 18, 2039method-of-use (U-4048)US 12569453
  • Nov 13, 2039method-of-use (U-4048)US 11497718
  • Nov 13, 2039method-of-use (U-2625)US 11590088
  • Nov 13, 2039method-of-use (U-4048)US 11938099
  • Nov 13, 2038compositionUS 10647649
  • Nov 13, 2038compositionUS 11597692
  • May 23, 2036formulationUS 10195160
  • May 19, 2036method-of-use (U-2625)US 10426743
  • May 19, 2036formulationUS 11458108
  • May 19, 2036method-of-use (U-2625)US 11612573
  • May 19, 2036formulationUS 11617724
  • May 19, 2036formulationUS 11622945

FDA exclusivities (2)

  • Dec 12, 2027I-956Indication (3y)1.3y
  • May 23, 2027NCENew Chemical Entity (5y)277d

News(0)

no news has mentioned this drug yet

brand
Vtama
generic
tapinarof
indication
Atopic Dermatitis (Atopic Eczema)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 22m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?